Plasma miR-136 can be used to screen patients with knee osteoarthritis from healthy controls by targeting IL-17

Abstract

The current study mainly evaluated the plasma level of microRNA (miR)-136 in knee osteoarthritis (KOA) patients and determined if miR-136 could be used as a potential biomarker to screen KOA patients from healthy controls. It was demonstrated that plasma miR-;136 was significantly decreased in the plasma of KOA patients. Moreover, the reduction in plasma miR-136 negatively correlated with the severity of KOA. Additionally, the increase in the serum interleukin (IL)-17 level positively correlated with the severity of KOA. More importantly, dual luciferase assays and western blot assays indicated that IL-17 was a target gene of miR-136. Further analysis showed that plasma miR-136 could be used as a biomarker to screen KOA patients from healthy controls. In summary, for the first time, the present study revealed that through targeting IL-17, decreased plasma miR-136 levels could be used as a potential biomarker to screen KOA patients from healthy controls.